contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-faron-pharmaceuticals-annual-report-a-potential-game-changer

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

clinicaltrialsregister.eu              Clinical Trials Register                              This is the official page

Old information. It was initially planned as an investigator-initiated trial. In that text, there is a link to this previous clinical trials page ClinicalTrials.gov. That study was initially planned under the name Bexlung, but now I suppose Blaze replaces that and Gilead’s molecule acts as the PD-1 inhibitor.

I read that halfway through and then I came across something strange. Smarter people can explain this again. Merck’s Pembro has been added to the “Pembrolizumab, azacitidine, venetoclax” combination therapies? Was that just thrown in there as a joke? That is the holy grail of cancer drugs if someone doesn’t know yet. Or actually, it’s not the fountain of youth but the Sampo from our Kalevala.

In my opinion, a very objective explanation/listing of what BEX is currently being studied for can be found on the EU clinical trials website. Text that is understandable almost even for a layman: https://clinicaltrials.eu/drug/bexmarilimab/

Let’s talk about what’s missing. What does it look like from the perspective of the other negotiating party? Sentiment is improving because interest rates are falling and patents worth 300 BUSD are expiring. This is from an M&A angle, but probably applies equally to licensing. Mid-caps are also mentioned in addition to big pharma. (Markku also spoke about these mid-caps as an opportunity when asked about partner discussions back in the day. Yes, discussions have also been held regarding MATINS and Traumakine. Faron licensed Traumakine to Korea https://www.biospace.com/faron-pharmaceuticals-ltd-licenses-traumakine-korean-rights-to-b-pharmbio-korea-inc-b-pharmbio and to Japan, China, Taiwan, Hong Kong. The Chinese subsequently sold their stake. Faron and CMS enter into Traumakine agreement The use of Traumakine in phase 3 with corticosteroids was unsuccessful and scuttled the deals. Fortunately, there is a new patent now.)                   BioSpace – 17 Dec 25              Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites    2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.                             Another article from the same area. Deal-making will increase in 2026 as the industry slump (does that sound familiar?) eases, partly due to US politics. China is rising.                   BioSpace – 17 Dec 25              Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback    Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.

Bayer’s Finnish operations have a turnover of almost a billion. Bayer pays more corporate tax to Finland.

Denmark has no forests, so there Novo (and a couple of other pharmaceutical companies) are responsible for GDP growth. In Finland, there’s only Orion and some minor players like e.g. Revenio. We’ll have to wait a long time for the pharmaceutical sector here to start dominating GDP volume. Of course, small biotech companies like Faron could also contribute to the growth of national wealth in some distant future

Faron Pharmaceuticals

Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report and clinical progress with lead candidate Bexmarilimab. We make some adjustments to our...

<div class="mfn-body"><p>Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report and clinical progress with lead candidate Bexmarilimab. We make some adjustments to our overall estimates following a revision of our model. Accordingly, as we continue to see a compelling case rooted in an exciting pipeline, we revise our fair value range and raise our base case valuation.</p><p><a rel="noopener" href="https://www.redeye.se/research/887741/faron-pharmaceuticals-h2-report-a-potential-game-changer">Read more and download the Research Update.</a></p><p>Follow companies at Redeye to receive the latest equity research within Life Science and Technology.</p><p>This is a press release from Redeye - Research Powered Investment Banking. <a rel="noopener" href="https://www.redeye.se/">www.redeye.se/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/7dd524fa-8c66-472f-bb7e-9ab5babd081f/faron-pharmaceuticals-annual-report-a-potential-game-changer.pdf" class="mfn-generated mfn-primary">Faron Pharmaceuticals Annual report - A potential game-changer</a></p></div>